<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Series D</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts</title>
      <description>
        <![CDATA[Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730423</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730423-oricell-raises-110m-in-pre-ipo-round-to-advance-solid-tumor-car-ts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-anatomy-on-medical-background.webp?t=1775850555" type="image/jpeg" medium="image" fileSize="591366">
        <media:title type="plain">Liver anatomy on medical background</media:title>
      </media:content>
    </item>
    <item>
      <title>Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts</title>
      <description>
        <![CDATA[Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730221</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730221-oricell-raises-110m-in-pre-ipo-round-to-advance-solid-tumor-car-ts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-anatomy-on-medical-background.webp?t=1775850555" type="image/jpeg" medium="image" fileSize="591366">
        <media:title type="plain">Liver anatomy on medical background</media:title>
      </media:content>
    </item>
    <item>
      <title>With $80M series D, Life Biosciences advances epigenetic reprogramming  </title>
      <description>
        <![CDATA[Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the biological effects of aging via partial epigenetic reprogramming.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730208</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730208-with-80m-series-d-life-biosciences-advances-epigenetic-reprogramming</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation-variation.webp?t=1722524925" type="image/jpeg" medium="image" fileSize="179355">
        <media:title type="plain">Illustration of double helix </media:title>
      </media:content>
    </item>
    <item>
      <title>Corxel raises $287M series D round to advance oral GLP-1</title>
      <description>
        <![CDATA[Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728500</guid>
      <pubDate>Tue, 27 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728500-corxel-raises-287m-series-d-round-to-advance-oral-glp-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/White-tabletl-with-dollar-sign-imprint.webp?t=1764186016" type="image/jpeg" medium="image" fileSize="192346">
        <media:title type="plain">White tablet imprinted with dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>1st Biotherapeutics closes $22M series D, preps for IPO</title>
      <description>
        <![CDATA[1st Biotherapeutics Inc. announced the closing of a ₩31.7 billion series D funding round Jan. 26 to advance its lead phase I oncology asset, FB-849, and portfolio of candidates for neurodegenerative diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728499</guid>
      <pubDate>Tue, 27 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728499-1st-biotherapeutics-closes-22m-series-d-preps-for-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-Korean-Won-sign.webp?t=1731708866" type="image/jpeg" medium="image" fileSize="105191">
        <media:title type="plain">Korean Won currency symbol made of gray cast iron</media:title>
      </media:content>
    </item>
    <item>
      <title>1st Biotherapeutics closes $22M series D, preps for IPO</title>
      <description>
        <![CDATA[1st Biotherapeutics Inc. announced the closing of a ₩31.7 billion series D funding round Jan. 26 to advance its lead phase I oncology asset, FB-849, and portfolio of candidates for neurodegenerative diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728319</guid>
      <pubDate>Mon, 26 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728319-1st-biotherapeutics-closes-22m-series-d-preps-for-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-Korean-Won-sign.webp?t=1731708866" type="image/jpeg" medium="image" fileSize="105191">
        <media:title type="plain">Korean Won currency symbol made of gray cast iron</media:title>
      </media:content>
    </item>
    <item>
      <title>Corxel raises $287M series D round to advance oral GLP-1</title>
      <description>
        <![CDATA[Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728169</guid>
      <pubDate>Fri, 23 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728169-corxel-raises-287m-series-d-round-to-advance-oral-glp-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/White-tabletl-with-dollar-sign-imprint.webp?t=1764186016" type="image/jpeg" medium="image" fileSize="192346">
        <media:title type="plain">White tablet imprinted with dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Vicentra secures additional $13M for Kaleido insulin patch pump</title>
      <description>
        <![CDATA[Investors poured a further $13 million into Vicentra BV for Kaleido, its insulin patch pump system, taking the total raised in the company’s series D financing round to $98 million. The funds come amid significant changes across diabetes technology, particularly the acceleration of patch pumps. Kaleido is one of the smallest, lightest, and most precise insulin patch pumps available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727605</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727605-vicentra-secures-additional-13m-for-kaleido-insulin-patch-pump</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Kaleido-user-9jam26.webp?t=1767995539" type="image/jpeg" medium="image" fileSize="150989">
        <media:title type="plain">Kaleido user</media:title>
        <media:description type="plain">Kaleido insulin patch pump system. Credit: Vincentra</media:description>
      </media:content>
    </item>
    <item>
      <title>Artios raises $115M series D for potential first-in-class programs</title>
      <description>
        <![CDATA[DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase I/IIa data for its two lead programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726238</guid>
      <pubDate>Mon, 17 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726238-artios-raises-115m-series-d-for-potential-first-in-class-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-dna-diagnostic.webp?t=1682529493" type="image/png" medium="image" fileSize="705763">
        <media:title type="plain">Cancer cell, DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Cornerstone Robotics raises $200M series D round</title>
      <description>
        <![CDATA[Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725991</guid>
      <pubDate>Fri, 14 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725991-chinas-cornerstone-robotics-raises-200m-series-d-round</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Cornerstone-Robotics-Sentire-Surgical-System-12nov25.webp?t=1763154095" type="image/jpeg" medium="image" fileSize="147992">
        <media:title type="plain">Cornerstone Robotics Sentire Surgical System</media:title>
        <media:description type="plain">Cornerstone Robotics Sentire Surgical System. Credit: Cornerstone Robotics Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Synchron raises $200M to accelerate Stentrode BCI platform</title>
      <description>
        <![CDATA[Synchron Inc.'s recent $200 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the technology. Advances in BCI development, ongoing clinical trials and growing market demand are drawing increased investor interest in the technology which has the potential to transform the lives of millions of people. At the same time, government agencies are closely monitoring the field, recognizing the potential while urging caution about the risks involved.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725949</guid>
      <pubDate>Mon, 10 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725949-synchron-raises-200m-to-accelerate-stentrode-bci-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Stentrode-BCI-10nov25.webp?t=1762810749" type="image/jpeg" medium="image" fileSize="127755">
        <media:title type="plain">Stentrode BCI</media:title>
        <media:description type="plain">Stentrode brain-computer interface. Credit: Synchron</media:description>
      </media:content>
    </item>
    <item>
      <title>Series D financing at Dewpoint to advance c-mod DPTX-3186</title>
      <description>
        <![CDATA[Dewpoint Therapeutics Inc. has closed its series D financing to advance DPTX-3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end and deliver early clinical proof of concept in gastric cancer by the end of next year. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/724040</guid>
      <pubDate>Fri, 12 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724040-series-d-financing-at-dewpoint-to-advance-c-mod-dptx-3186</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Vicentra raises $85M for Kaleido insulin patch pump</title>
      <description>
        <![CDATA[Vicentra BV’s insulin patch pump, Kaleido, will soon reach more patients with diabetes after it raised $85 million in a series D funding round. The company said the Kaleido is among the smallest, lightest, and most precise insulin patch pumps available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723561</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723561-vicentra-raises-85m-for-kaleido-insulin-patch-pump</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/User-with-Kaleido-3sept25.webp?t=1756934843" type="image/jpeg" medium="image" fileSize="441344">
        <media:title type="plain">User with Kaleido</media:title>
        <media:description type="plain">User with Kaleido. Credit: Vicentra</media:description>
      </media:content>
    </item>
    <item>
      <title>Setpoint sports back-to-back wins with  FDA approval, $140M raise</title>
      <description>
        <![CDATA[In less than two weeks, Setpoint Medical Inc. mastered the power serve with the first approval of a neuroimmune modulation device to manage rheumatoid arthritis, followed by a $25 million second tranche of its series C and a $115 million series D financing round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722823</guid>
      <pubDate>Mon, 11 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722823-setpoint-sports-back-to-back-wins-with-fda-approval-140m-raise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/SETPOINT-11aug25.webp?t=1754949865" type="image/jpeg" medium="image" fileSize="79199">
        <media:title type="plain">Setpoint vagus nerve stimulation device</media:title>
        <media:description type="plain">Setpoint vagus nerve stimulation device. Credit Setpoint Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>Avalyn secures $100M for inhaled pulmonary fibrosis candidates</title>
      <description>
        <![CDATA[Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an oversubscribed series D financing round to support development of its inhaled treatments for pulmonary fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722492</guid>
      <pubDate>Wed, 23 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722492-avalyn-secures-100m-for-inhaled-pulmonary-fibrosis-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Avalyn-inhaler-7-22.webp?t=1753219889" type="image/png" medium="image" fileSize="371608">
        <media:title type="plain">Avalyn inhaler</media:title>
        <media:description type="plain">Avalyn Pharma Inc. is developing inhaled treatments for pulmonary fibrosis. Credit: Avalyn Pharma Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Avalyn secures $100M for inhaled pulmonary fibrosis candidates</title>
      <description>
        <![CDATA[Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an oversubscribed series D financing round to support development of its inhaled treatments for pulmonary fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722334</guid>
      <pubDate>Tue, 22 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722334-avalyn-secures-100m-for-inhaled-pulmonary-fibrosis-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Avalyn-inhaler-7-22.webp?t=1753219889" type="image/png" medium="image" fileSize="371608">
        <media:title type="plain">Avalyn inhaler</media:title>
        <media:description type="plain">Avalyn Pharma Inc. is developing inhaled treatments for pulmonary fibrosis. Credit: Avalyn Pharma Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Forsight Robotics secures $125M for eye surgery robotics platform</title>
      <description>
        <![CDATA[Forsight Robotics Ltd. secured $125 million in series B financing for its Oryom platform, a robotic system for cataract surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721248</guid>
      <pubDate>Fri, 27 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721248-forsight-robotics-secures-125m-for-eye-surgery-robotics-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Close-up-of-eye-and-vision-test.webp?t=1730493501" type="image/jpeg" medium="image" fileSize="159676">
        <media:title type="plain">Close up of eye and vision test</media:title>
      </media:content>
    </item>
    <item>
      <title>Allay’s $57.5M extends postsurgical pain relief with ATX-101</title>
      <description>
        <![CDATA[As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment from the company’s Japanese partner.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721154</guid>
      <pubDate>Tue, 10 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721154-allays-575m-extends-postsurgical-pain-relief-with-atx-101</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Knee-pain-illustration.webp?t=1620931981" type="image/png" medium="image" fileSize="380724">
        <media:title type="plain">Knee pain illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Allay’s $57.5M extends postsurgical pain relief with ATX-101</title>
      <description>
        <![CDATA[As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment from the company’s Japanese partner. ATX-101, a configuration of sodium ion channel blocker bupivacaine and a biopolymer, which is in a phase IIb registration study, is designed to offer pain relief following total knee arthroplasty.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720951</guid>
      <pubDate>Fri, 06 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720951-allays-575m-extends-postsurgical-pain-relief-with-atx-101</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Knee-pain-illustration.webp?t=1620931981" type="image/png" medium="image" fileSize="380724">
        <media:title type="plain">Knee pain illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Grin’s radiprodil heads to phase III with $570M deal, $140M series D</title>
      <description>
        <![CDATA[A new version of a drug candidate that failed in a phase II for neuropathic pain 15 years ago has attracted $140 million in series D funds, plus an ex-North American deal worth up to $570 million, for Grin Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720485</guid>
      <pubDate>Tue, 27 May 2025 15:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720485-grins-radiprodil-heads-to-phase-iii-with-570m-deal-140m-series-d</link>
    </item>
    <item>
      <title>Keeping a bead on TEAD in mesothelioma, Vivace raises $35M more</title>
      <description>
        <![CDATA[Vivace Therapeutics Inc. closed a $35 million series D round led by RA Capital Management, an existing investor, and including other backers already on board: Canaan Partners and Cenova Capital. Proceeds will support the continued development of what the company describes as its first-in-class and best-in-class transcriptional enhanced associate domain autopalmitoylation (TEAD) inhibitor, VT-3989, with an initial focus on mesothelioma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718123</guid>
      <pubDate>Wed, 12 Mar 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718123-keeping-a-bead-on-tead-in-mesothelioma-vivace-raises-35m-more</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Mesothelioma.webp?t=1686261343" type="image/jpeg" medium="image" fileSize="232237">
        <media:title type="plain">Mesothelioma</media:title>
      </media:content>
    </item>
    <item>
      <title>4C raises $175M for mitral valve technology</title>
      <description>
        <![CDATA[4C Medical Technologies Inc. raised $175 million in a series D financing round led by Boston Scientific Corp. The financing will support the regulatory trials and commercialization of the Altavalve system, a transcatheter mitral valve replacement (TMVR) technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717735</guid>
      <pubDate>Thu, 06 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717735-4c-raises-175m-for-mitral-valve-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>Eikon tops the year’s VC rounds as it enters a phase III in cancer</title>
      <description>
        <![CDATA[With the closing of its $350.7 million series D, Eikon Therapeutics Inc. has notched two financial high marks for the still young year. The funding is the biggest venture capital round of 2025 and it’s also the first series D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717762</guid>
      <pubDate>Wed, 26 Feb 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717762-eikon-tops-the-years-vc-rounds-as-it-enters-a-phase-iii-in-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Alfred-Bowie-chief-financial-officer-Eikon-2026.webp?t=1740609292" type="image/jpeg" medium="image" fileSize="174117">
        <media:title type="plain">Alfred Bowie, chief financial officer, Eikon</media:title>
        <media:description type="plain">Alfred Bowie, chief financial officer, Eikon Therapeutics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Ōura closes $200M series D, Dexcom invests $75M</title>
      <description>
        <![CDATA[Dexcom Inc. put real money behind expanding its integration efforts, with a $75 million investment in the $200 million series D for Ōura Health Oy, the maker of the Ōura smart ring. Ōura and Dexcom also provided details on a strategic partnership that integrates data from Dexcom’s continuous glucose monitors with vital sign, sleep, stress, heart health and activity data from the Ōura ring.    ]]>
      </description>
      <guid>http://www.bioworld.com/articles/715224</guid>
      <pubDate>Thu, 19 Dec 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715224-ura-closes-200m-series-d-dexcom-invests-75m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Oura-Ring-19dec24.webp?t=1760478501" type="image/jpeg" medium="image" fileSize="394173">
        <media:title type="plain">Oura Ring</media:title>
        <media:description type="plain">Oura ring. Credit: Oura Health Oy</media:description>
      </media:content>
    </item>
    <item>
      <title>Alentis adds $181M in series D for Claudin-1-focused ADC trials</title>
      <description>
        <![CDATA[Alentis Therapeutics SA is poised to expand its reach in Claudin-1 biology, after closing a $181.4 million series D that will fund phase I/II trials of two antibody-drug conjugates (ADCs) targeting the transmembrane protein, which is overexpressed on a number of squamous cell tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714427</guid>
      <pubDate>Tue, 12 Nov 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714427-alentis-adds-181m-in-series-d-for-claudin-1-focused-adc-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Grey-dollar-sign-on-grey-background.webp?t=1637008345" type="image/png" medium="image" fileSize="894498">
        <media:title type="plain">Grey dollar sign on grey background</media:title>
      </media:content>
    </item>
    <item>
      <title>Huma Therapeutics raises $80M in series D for growth</title>
      <description>
        <![CDATA[The $80 million in financing that Huma Therapeutics Ltd. recently raised is a testament to where the company is and what it achieved at a time when the digital health industry is struggling to raise significant financing, Mert Aral, chief medical officer at Huma, told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710935</guid>
      <pubDate>Tue, 30 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710935-huma-therapeutics-raises-80m-in-series-d-for-growth</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-with-bar-chart.webp?t=1707510184" type="image/jpeg" medium="image" fileSize="103185">
        <media:title type="plain">DNA with bar chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Tricares raises $50M in series D for tricuspid heart valve replacement system</title>
      <description>
        <![CDATA[Tricares SAS raised $50 million in a series D financing round to support upcoming clinical trials in the U.S. and EU for its transfemoral tricuspid heart valve replacement system, Topaz.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710445</guid>
      <pubDate>Thu, 25 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710445-tricares-raises-50m-in-series-d-for-tricuspid-heart-valve-replacement-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/TRiCares-topaz-25july24.webp?t=1721940803" type="image/jpeg" medium="image" fileSize="130295">
        <media:title type="plain">TRiCares Topaz</media:title>
        <media:description type="plain">Tricares Topaz transfemoral tricuspid heart valve replacement system. Credit: Tricares</media:description>
      </media:content>
    </item>
    <item>
      <title>Catalym’s GDF15-targeting cancer drug draws $150M series D</title>
      <description>
        <![CDATA[Catalym GmbH has closed a $150 million series D to take its first in class immune potentiator visugromab into phase IIb development in a number of solid tumors. The round follows on the heels of data from a phase I/IIa trial which showed visugromab in combination with the PD-1 inhibitor antibody Opdivo (nivolumab, Bristol Myers Squibb) increased T-cell infiltration and generated durable antitumor responses in patients who had exhausted all other treatment options.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710611</guid>
      <pubDate>Tue, 16 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710611-catalyms-gdf15-targeting-cancer-drug-draws-150m-series-d</link>
    </item>
    <item>
      <title>Kardium enters pulsed field ablation market with $104M financing</title>
      <description>
        <![CDATA[Kardium Inc. landed $104 million in new financing for its Globe mapping and ablation system for atrial fibrillation, positioning it to enter the rapidly changing field in the U.S. The funds will allow the company to finish its PULSAR trial, secure FDA approval and launch its pulsed field ablation system commercially, Kardium Chief Financial Officer Koert VandenEnden told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709250</guid>
      <pubDate>Tue, 11 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709250-kardium-enters-pulsed-field-ablation-market-with-104m-financing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/image-single-shot-pvi-11june24.webp?t=1718145238" type="image/jpeg" medium="image" fileSize="126074">
        <media:title type="plain">Single Shot PVI</media:title>
        <media:description type="plain">Kardium Inc.’s Globe integrated mapping and pulsed field ablation system. Credit: Kardium Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>$170M banked, Bioage phase II to test GLP-1/apelin combo</title>
      <description>
        <![CDATA[Bioage Labs Inc.’s $170 million series D financing will pay for phase II trials with azelaprag, an apelin receptor agonist, to be tried in combination with Zepbound (tirzepatide), the glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist from Bioage partner Eli Lilly and Co.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705791</guid>
      <pubDate>Tue, 13 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705791-170m-banked-bioage-phase-ii-to-test-glp-1-apelin-combo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Grey-dollar-sign-on-grey-background.webp?t=1637008345" type="image/png" medium="image" fileSize="894498">
        <media:title type="plain">Grey dollar sign on grey background</media:title>
      </media:content>
    </item>
  </channel>
</rss>
